8-K: Orgenesis Stock Downgraded to Pink Limited Tier Amidst Delinquent 10-K Filing

Orgenesis Inc. has announced its common stock will be moved from OTCQX to the Pink Limited tier due to its failure to file its annual 10-K report for the period ending December 31, 2024.

Summary

• Orgenesis Inc. (ORGS) was notified by OTC Markets Group on June 2, 2025, that its common stock would be moved from OTCQX to the Pink Limited tier, effective June 3, 2025.
• This delisting is a direct consequence of the company's delinquency in filing its 10-K report for the period ending December 31, 2024.
• The company previously received a notice on April 17, 2025, regarding this delinquency, which violates Section 2.2 (A)(1)(i) of the OTCQX Rules for U.S. Companies requiring all annual, quarterly, and interim reports on EDGAR.
• Orgenesis Inc. was unable to remedy this deficiency within the 45-day cure period provided by OTC Markets.

Sentiment

Score: 1

Explanation: The delisting due to failure to meet basic reporting requirements is a highly negative event, indicating significant operational or financial distress and severely impacting investor confidence and stock liquidity.

Negatives

• The company's common stock has been downgraded from the OTCQX tier to the less transparent Pink Limited tier, effective June 3, 2025.
• This downgrade is a direct result of the company's failure to file its annual 10-K report for the period ending December 31, 2024, making it non-compliant with OTCQX listing requirements.
• Orgenesis Inc. failed to remedy the filing deficiency within the 45-day cure period, indicating a persistent issue with financial reporting compliance.

Risks

• Reduced liquidity and market visibility for the company's common stock due to its move to the Pink Limited tier.
• Potential erosion of investor confidence due to non-compliance with financial reporting requirements and the subsequent delisting.
• Increased difficulty in raising capital or securing financing given the company's inability to meet basic SEC filing obligations.
• Risk of further regulatory scrutiny or enforcement actions from the SEC or other bodies due to ongoing reporting delinquencies.

Future Outlook

NA

Management Comments

• No specific management quotes or statements were provided in this filing beyond the signatory, Victor Miller, Chief Financial Officer, Treasurer and Secretary.

Industry Context

This announcement is specific to Orgenesis Inc.'s compliance with listing requirements and does not reflect broader industry trends. The failure to file a required annual report and subsequent delisting is a company-specific operational and governance issue, rather than an industry-wide challenge.

Comparison to Industry Standards

• The failure to file a timely 10-K report and subsequent delisting from OTCQX to the Pink Limited tier represents a significant deviation from standard corporate governance and financial reporting practices expected of publicly traded companies.
• Reputable companies across industries, including those in biotechnology and healthcare like Orgenesis, are expected to maintain strict compliance with SEC filing deadlines and exchange listing requirements to ensure transparency and investor confidence. This situation places Orgenesis significantly below industry benchmarks for regulatory compliance.

Stakeholder Impact

• Shareholders will experience reduced liquidity and potentially lower stock valuation due to the move to the Pink Limited tier, which typically has less transparency and fewer trading participants.
• The company's ability to attract new investors or secure financing may be negatively impacted due to its non-compliance and reduced market visibility.

Key Dates

Recommendation

Keywords

Orgenesis Inc., ORGS, OTCQX, Pink Limited, Delisting, SEC filing, 10-K, Financial reporting, Compliance, Current Report, OTC Markets Group